Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream (AIJP)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
University of California, San Francisco Identifier:
First received: February 13, 2008
Last updated: October 8, 2013
Last verified: October 2013

The purpose of this study is to find out if a Chinese herbal cream is effective in treating HSIL (high-grade squamous intraepithelial lesions, also known as HGAIN, or high-grade anal intraepithelial neoplasia).

Condition Intervention Phase
Anus Neoplasms
Drug: AIJP (Arnebia Indigo Jade Pearl)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Pathologic response (progression, no change, or regression) of anal HSIL to treatment with the topical cream versus treatment with placebo [ Time Frame: Clinical assessment at screen, week 24, week 48, and follow up at week 60 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate treatment adherence and drop-out rates, and obtain effect size for Phase 3 trial [ Time Frame: Week 24, week 48, and week 60 ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: March 2008
Estimated Study Completion Date: January 2014
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: AIJP (Arnebia Indigo Jade Pearl)
Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
Placebo Comparator: 2 Drug: Placebo
Placebo twice daily for 48 weeks.

Detailed Description:

The purpose of this study is to test a new noninvasive topical cream, AIJP (Arnebia Indigo Jade Pearl), for treatment of precancerous anal lesions in order to prevent their progression to anal cancer. AIJP is a topical Chinese herbal cream that has been specifically designed to treat people with the cancer precursor lesions caused by human papillomavirus (HPV). In general, HPV infection is a key factor in development of cervical, anal and vulvar cancers. People with HIV are especially vulnerable to develop anal cancer associated with HPV. It is known that prior to development of anal cancer a person develops a precancerous condition known as a high-grade squamous intraepithelial lesion (HSIL). Treatment of the HSIL can prevent progression to anal cancer. Current therapies for HSIL and anal cancer are highly invasive. A new effective noninvasive topical therapy for precancerous HSIL could have a high impact on prevention of anal cancer.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Anal HSIL confirmed by biopsy no more than 30 days prior to entry
  • Anal HSIL deemed not amenable to therapy or participant declines routine ablative therapy
  • HIV positive
  • Stable HIV treatment regimen for at least 8 weeks prior to entry
  • At least 18 years of age
  • Women of childbearing potential must use contraception
  • Platelet count above 70,000/mm3 within 30 days prior to entry
  • ANC greater or equal to 1000/mm3 within 30 days prior to entry
  • Creatinine less then or equal to 1.5 times ULN within 30 days prior to entry
  • AST and ALT less than or equal to 3 times ULN within 30 days prior to entry

Exclusion Criteria:

  • Prior history of invasive anal, cervical, vaginal, or vulvar cancer
  • Pregnancy or lactation and breast-feeding
  • Must not participate in a conception process including sperm donation
  • Medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with ability to comply with protocol
  • Known allergy to any topical cream components
  • Patients with lesions clinically suspicious per HRA examiner for early progression (less than one year) to anal cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00622440

United States, California
UCSF Mt. Zion Medical Center, 1600 Divisadero St., Box 1699
San Francisco, California, United States, 94143-1699
Sponsors and Collaborators
University of California, San Francisco
Principal Investigator: Misha R Cohen, OMD, LAc Institute for Health and Aging, UCSF School of Nursing
  More Information

Additional Information:
No publications provided

Responsible Party: University of California, San Francisco Identifier: NCT00622440     History of Changes
Other Study ID Numbers: CCRC 5031, CC # 07501, CTRF Grant # P-07-020
Study First Received: February 13, 2008
Last Updated: October 8, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Francisco:
Traditional Chinese Medicine

Additional relevant MeSH terms:
Anus Neoplasms
Uterine Cervical Dysplasia
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases
Precancerous Conditions
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female processed this record on July 20, 2014